Company Kodiak Sciences Inc.

Equities

KOD

US50015M1099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.18 ^USD	+5.30%		+3.58%	+4.61%

May. 15	Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 14	Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy	CI

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Number of employees: 107

Managers	Title	Age	Since
Victor Perlroth CEO	Chief Executive Officer	51	08-12-31
John Borgeson DFI	Director of Finance/CFO	62	15-12-31
Pablo Velazquez-Martin CTO	Chief Tech/Sci/R&D Officer	-	-
Almas Qudrat PRN	Corporate Officer/Principal	-	17-12-31

Members of the board	Title	Age	Since
Felix Baker BRD	Director/Board Member	55	15-08-31
Tai Yin Yang BRD	Director/Board Member	70	19-12-16
Richard Levy BRD	Director/Board Member	66	18-07-17
Robert Profusek BRD	Director/Board Member	73	18-05-31
Bassil Dahiyat BRD	Director/Board Member	53	18-07-17
Victor Perlroth CEO	Chief Executive Officer	51	08-12-31
Charles Bancroft BRD	Director/Board Member	65	20-04-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	52,534,947	49,562,960 ( 94.34 %)	0	94.34 %

Name	Equities	%	Valuation
Baker Bros. Advisors LP 32.96 %	17,310,490	32.96 %	55 M $
BlackRock Advisors LLC 7.113 %	3,735,749	7.113 %	12 M $
Victor Perlroth 5.131 %	2,695,038	5.131 %	9 M $
Acadian Asset Management LLC 3.280 %	1,722,890	3.280 %	5 M $
Vanguard Fiduciary Trust Co. 3.150 %	1,654,448	3.150 %	5 M $
EcoR1 Capital, LLC 3.072 %	1,613,600	3.072 %	5 M $
SilverArc Capital Management LLC 2.359 %	1,238,822	2.359 %	4 M $
D.E. Shaw & Co., Inc. 1.989 %	1,044,650	1.989 %	3 M $
ICONIQ Capital LLC 1.936 %	1,016,864	1.936 %	3 M $
Newtyn Management LLC 1.904 %	1,000,000	1.904 %	3 M $

Kodiak Sciences, Inc.

1200 Page Mill Road

94304, Palo Alto

+650 281 0850

http://www.kodiak.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.18 USD

Average target price

4.25 USD

Spread / Average Target

+33.65%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KODIAK SCIENCES INC.	+4.61%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs